@article{084456c25a384e3b9927412a900153d5,
title = "Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein",
author = "Zhu, \{Andrew X.\} and Finn, \{Richard S.\} and Galle, \{Peter R.\} and Llovet, \{Josep M.\} and Masatoshi Kudo",
note = "Funding Information: AXZ reports grants from Bayer, Bristol-Myers Squibb, Eli Lilly, Merck, and Novartis, and consultancy fees and advisory roles for AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Eli Lilly, Exelixis, Merck, Novartis, and Roche Genentech. RSF reports consultancy fees for AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Pfizer, Merck, Novartis, Roche Genentech, and Exelixis. PRG reports advisory board and lecture fees from Bayer, Bristol-Myers Squibb, MSD, Merck, Sirtex, AstraZeneca, Sillajen, and Eli Lilly. JML reports grants from Bayer Healthcare, Bristol-Myers Squibb, Eisai, Ipsen, Blueprint, and Incyte, and personal fees from Eli Lilly, Bayer Healthcare, Bristol-Myers Squibb, Eisai, Blueprint, Incyte, Celsion, Exelixis, Glycotest, Ipsen, Merck, Navigant, Leerink Swann, Midatech, Fortress Biotech, Spring Bank Pharmaceuticals, and Nucleix. MK reports grants from Chugai, Otsuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai, Bayer, AbbVie, Medico's Hirata, Astellas, and Bristol-Myers Squibb, and has served on advisory boards for Bayer, Eisai, MSD, Ajinomoto, Kowa, Bristol-Myers Squibb, Chugai, Taiho, Eisai, and Ono.",
year = "2019",
month = apr,
doi = "10.1016/S1470-2045(19)30165-2",
language = "English",
volume = "20",
pages = "e191",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Elsevier Ltd.",
number = "4",
}